Skip to main content
Clinical Trials/IRCT20231229060558N1
IRCT20231229060558N1RecruitingPhase 3

Evaluation of the efficacy of probiotics in Nonalcoholic Fatty Liver Disease treatmenth

Mashhad University of Medical Sciences0 sites120 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
120

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20 years to 75 years (—)
Sex
All

Inclusion Criteria

  • People between 20 and 75 years old with confirmed fatty liver in Persian Cohort of Mashhad

Exclusion Criteria

  • Liver failure
  • Suffering from hepatitis (viral, autoimmune, metabolic, medicinal)
  • History of alcohol consumption
  • People with ALT or AST more than 5 times normal •
  • Pregnant people
  • Taking drugs that can cause hepatic steatosis, including antiarrhythmic drugs (Amiodarone) ), anti-metabolite antineoplastic drugs (methotrexate), hormonal antineoplastic drugs (tamoxifen), corticosteroids, anticonvulsant drugs, antiretroviral drugs
  • use of antihypertensive drugs, vastatins)
  • known hereditary defects (iron and copper). Storage diseases and alpha 1 antitrypsin deficiency

Investigators

Similar Trials